Loading clinical trials...
Loading clinical trials...
A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis
Conditions
Interventions
Placebo
AEB071
Locations
40
United States
Burke Pharmaceutical Research
Hot Springs, Arizona, United States
Belleair Research Center, LLC
Pinellas Park, Florida, United States
Kansas City Dermatology, PA
Overland Park, Kansas, United States
Dermatology Specialists
Louisville, Kentucky, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Central Dermatology
St Louis, Missouri, United States
Start Date
April 1, 2009
Primary Completion Date
August 1, 2011
Last Updated
December 22, 2020
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions